BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Price, Forecast & Analysis
USA - NASDAQ:BCRX - US09058V1035 - Common Stock
BCRX Key Statistics, Chart & Performance
The current stock price of BCRX is 7.355 USD. In the past month the price decreased by -1.09%. In the past year, price decreased by -14%.
BCRX Latest News, Press Relases and Analysis
BCRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.66 | 386.45B | ||
| AMGN | AMGEN INC | 13.65 | 160.24B | ||
| GILD | GILEAD SCIENCES INC | 14.61 | 148.49B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 109.35B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.46 | 69.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 351.12 | 59.83B | ||
| ARGX | ARGENX SE - ADR | 61.53 | 50.20B | ||
| INSM | INSMED INC | N/A | 39.82B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.04 | 34.33B | ||
| NTRA | NATERA INC | N/A | 27.09B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.09B | ||
| BIIB | BIOGEN INC | 9.25 | 22.70B |
Related stock screener links
About BCRX
Company Profile
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 580 full-time employees. The firm leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Company Info
BIOCRYST PHARMACEUTICALS INC
4505 Emperor Blvd Ste 200
Durham NORTH CAROLINA 27703 US
CEO: Jon P. Stonehouse
Employees: 580
Phone: 19198591302
BIOCRYST PHARMACEUTICALS INC / BCRX FAQ
Can you describe the business of BIOCRYST PHARMACEUTICALS INC?
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The company is headquartered in Durham, North Carolina and currently employs 580 full-time employees. The firm leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
What is the stock price of BIOCRYST PHARMACEUTICALS INC today?
The current stock price of BCRX is 7.355 USD. The price increased by 1.45% in the last trading session.
What is the dividend status of BIOCRYST PHARMACEUTICALS INC?
BCRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BCRX stock?
BCRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is BIOCRYST PHARMACEUTICALS INC (BCRX) stock traded?
BCRX stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for BIOCRYST PHARMACEUTICALS INC?
BIOCRYST PHARMACEUTICALS INC (BCRX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the ownership details for BCRX stock?
You can find the ownership structure of BIOCRYST PHARMACEUTICALS INC (BCRX) on the Ownership tab.
BCRX Technical Analysis
BCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BCRX. Both the profitability and the financial health of BCRX get a neutral evaluation. Nothing too spectacular is happening here.
BCRX Financial Highlights
Over the last trailing twelve months BCRX reported a non-GAAP Earnings per Share(EPS) of -0.16. The EPS increased by 77.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.81% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BCRX Forecast & Estimates
17 analysts have analysed BCRX and the average price target is 17.99 USD. This implies a price increase of 144.58% is expected in the next year compared to the current price of 7.355.
For the next year, analysts expect an EPS growth of 120.49% and a revenue growth 39.07% for BCRX